1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow X-Linked Adrenoleukodystrophy: new trials by email Literature Review of X-Linked Adrenoleukodystrophy trials Research Report on X-Linked Adrenoleukodystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Sobetirome (NV1205) - X-Linked Adrenoleukodystrophy | Phase 1 / Phase 2 | Withdrawn | NeuroVia, Inc. | 2018-08-01 | 2019-03-07 |
Adrenal Gland Diseases (1) · Adrenal Insufficiency (1) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Central Nervous System Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Demyelinating Diseases (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hereditary Central Nervous System Demyelinating Diseases (1) · Heredodegenerative Disorders, Nervous System (1) · Intellectual Disability (1) · Leukoencephalopathies (1)
GC 1 compound (1)
NeuroVia, Inc. (1)
Argentina (1) · Australia (1) · Chile (1) · Colombia (1) · France (1) · Russia (1) · Ukraine (1) · United Kingdom (1)